Systems and methods of blocking a biological vessel 2 are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta- sheet spontaneously in an aqueous solution in the presence of a cation.

The present invention relates to a bioink for 3D printing, the preparation method, and the usage. Such bioink is a gel made of α-zein, porogen by 0-10% of the weight of zein, ethanol and water. The preparation method consists of: 10-50% zein is dissolved into an aqueous solution containing 40-90% (v/v) of ethanol, then, the porogen by 0-10% of the weight of zein is added, and then, this solution is allowed to stand at 5-95° C. for 1-10 days, or stirred for 30 min-24 hours, and thus, the bioink for 3D printing can be obtained. The conditions applied to prepare such bioink are mild and the method adopted is easy to operate, in addition, the said bioink for 3D printing has good mechanical properties and biocompatibility, which can be applied in the field of biomedicine for preparing tissue engineered substitutes and hemostatic materials by 3D printing at room temperature.

Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue.

The present disclosure provides medical products including an adhesive containing a carboxyalkyl cellulose and sorbitol. Such medical products can find use as a bolster material for use in conjunction with a surgical fastening device such as a stapler. Such adhesives may include advantageous properties such as the ability to retain tack while stored under a peelable cover. Related methods of manufacture and use are also described.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

A sheet-shaped tissue adhesive/reinforcement includes a base sheet having biodegradability and a communicative porous structure, and an adhesive resin layer fixed and formed on the base sheet. The adhesive resin layer includes a first reactant made of an aldehyded glycan and a second reactant made of partially carboxylated polylysine, and has a molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant. The adhesive resin layer has a structure of granules derived from powder of the first reactant, and a connecting layer derived from the second reactant. The connecting layer connects the granules to each other and fixes each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement.

The invention relates to the use of a polyphosphate salt as procoagulant mediator agent in medical devices or pharmaceutical compositions and the respective polyphosphate-containing medical devices and pharmaceutical compositions. The invention further relates to a method for preparing an aqueous fibroin solution by use of a microwave treatment. The invention further relates to a fibroin-containing structure produced or obtainable by the preparation method of the invention. The invention further comprises subsequent process steps leading to solidified fibroin products and to the use of said products for medical treatment.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

The present disclosure is generally directed to an embolic material in the form of a microparticle. The embolic material generally includes an alkene functionalized biopolymer. For instance, the embolic material may include a methacrylamide functionalized biopolymer. In some examples, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

The present invention relates to a self-assembling polypeptide for use as tissue adhesive. The present invention also relates to the use of a self-assembling polypeptide as tissue adhesive. Further, the invention is directed to the use of a self-assembling polypeptide to glue one or more cosmetic compounds on skin, mucosa, and/or hair. Furthermore, the invention is directed to a self-assembling polypeptide for use in gluing one or more pharmaceutical compounds on tissue, skin, mucosa, and/or hair.